SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

SCYNEXIS, Inc. reports financial results for the quarter ended March 31, 2017.

We analyze the earnings along side the following peers of SCYNEXIS, Inc. – Portola Pharmaceuticals, Inc. and Achaogen, Inc. (PTLA-US and AKAO-US) that have also reported for this period.

Highlights

  • Summary numbers: Revenues of USD 0.06 million, Net Earnings of USD -4.87 million.
  • Year-on-year change in operating cash flow of 24.42% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings growth from operating margin improvements as well as one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31
Relevant Numbers (Quarterly)
Revenues (mil) 0.06 0.06 0.06 0.06 0.06
Revenue Growth (%YOY) 0 0 0 0 -98.06
Earnings (mil) -4.87 -3.45 -11.23 -8.13 -7.18
Earnings Growth (%YOY) 32.22 58.88 -49.13 -25.2 -12.53
Net Margin (%) -7607.81 -5389.06 -17543.75 -12700 -11225
EPS -0.25 -0.14 -0.48 -0.56 -0.52
Return on Equity (%) -56.99 -40.58 -116.58 -82.39 -74.65
Return on Assets (%) -33.45 -22.84 -78.42 -69.02 -63.89

Access our Ratings and Scores for SCYNEXIS, Inc.

Market Share Versus Profits

Revenues History
Earnings History

SCYX-US‘s change in revenue this period compared to the same period last year of 0% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that SCYX-US is holding onto its market share. Also, for comparison purposes, revenues changed by 0% and earnings by -41.17% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

SCYX-US‘s change in operating cash flow of 24.42% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings

Margins

The company’s earnings growth has also been influenced by the following factors: (1) Improvements in operating (EBIT) margins from -11,095.31% to -9400% and (2) one-time items. The company’s pretax margins are now -7,607.81% compared to -11225% for the same period last year.

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for SCYNEXIS, Inc.

Company Profile

SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives which addresses the significant unmet therapeutic needs. It is currently developing a lead product candidate, SCY-078, a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Durham, NC.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of SCYX-US.